^
    8d
    RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs. (PubMed, J Immunother Cancer)
    Our study highlights the importance of understanding tumor-specific factors that limit CAR T-cell response and using this information to design superior next-generation CAR T-cells. Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    19d
    Autologous CAR-T Cells Targeting B7-H3 in PDAC (clinicaltrials.gov)
    P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Jun 2028 --> Apr 2030 | Trial primary completion date: Jun 2026 --> Apr 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CAR.B7-H3 T
    1m
    Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03. (PubMed, Neurooncol Pract)
    This study retrospectively applies TIAN criteria to patients with DIPG/pontine DMG treated with intraventricular B7-H3 CAR T cells in the BrainChild-03 (BC-03) trial (NCT04185038)...TIAN was common within this cohort but mostly low-grade and transient. Refining its classification and understanding its clinical impact will aid safety assessments and trial comparisons for CNS-directed CAR T therapies.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    1m
    Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=9, Recruiting, Chulalongkorn University | Trial primary completion date: Dec 2026 --> Dec 2027 | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule) • IL7R (Interleukin 7 Receptor)
    1m
    Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    2ms
    Study of Intracerebroventricular MT027 in Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, T-MAXIMUM Pharmaceutical Inc
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
    |
    MT027
    2ms
    A Dose-escalation and Dose-expansion Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile, and Efficacy of MT027 Cell Injection in Patients with Lung Cancer Complicated by Brain and/or Leptomeningeal Metastases (ChiCTR2600116919)
    P1, N=22, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P1 trial
    |
    CD276 (CD276 Molecule)
    |
    MT027
    2ms
    A Phase I Dose-Escalation and Dose-Expansion Clinical Study Evaluating the Tolerability, Safety, Pharmacokinetics , and Efficacy of MT027 Cell Injection in Patients with Triple-Negative Breast Cancer and Brain Metastases (ChiCTR2600116792)
    P1, N=22, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD276 (CD276 Molecule)
    |
    ER negative
    |
    MT027
    5ms
    Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas (clinicaltrials.gov)
    P1, N=42, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • B7-H3 CAR-T
    5ms
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    5ms
    Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=85, Recruiting, Tcelltech Inc.
    New P1 trial
    5ms
    A single-arm, dose-escalation, exploratory clinical study to evaluate the tolerability, safety, pharmacokinetic profile and preliminary efficacy of MT027 cell injection in patients with malignant solid tumours metastatic to the brain, brain (spinal) membrane and spinal cord (ChiCTR2500107346)
    P=N/A, N=9, Recruiting, FuJIan SanBo FuNeng Brain Hospital; FuJIan SanBo FuNeng Brain Hospital
    New trial
    |
    CD276 (CD276 Molecule)
    |
    MT027